RBCs manufactured either from whole blood (WB) or using apheresis devices are typically leukoreduced and stored in the liquid state suspended in a crystalloid additive solution (AS) in a refrigerator at 1°C to 6°C. Under these conditions, the maximum storage is 42 days in the US. During liquid storage, changes occur in the RBCs and in the supernatant which collectively are described as the RBC storage lesion.
Results: Ninety day 42 and 218 day 7 to day 39 RBCs showed a mean ± SD supernatant hemoglobin of 75 ± 100 vs 25.5 ± 16 mg/dL respectively (P < .01). Supernatant hemoglobin correlated weakly with storage age (r = 0.2, P < .01) but more strongly with hematocrit (r = 0.4, P < .01).

Conclusions: There are minimal differences in supernatant hemoglobin until the final days of liquid storage when some high hematocrit RBCs show excessive hemolysis.
RBCs manufactured either from whole blood (WB) or using apheresis devices are typically leukoreduced and stored in the liquid state suspended in a crystalloid additive solution (AS) in a refrigerator at 1°C to 6°C. Under these conditions, the maximum storage is 42 days in the US. During liquid storage, changes occur in the RBCs and in the supernatant which collectively are described as the RBC storage lesion. 1 Details of the various changes are discussed elsewhere. [2] [3] [4] One of the more prominent changes is the occurrence of hemolysis or leakage of hemoglobin from the intact RBC. 5 Such hemoglobin may be free in solution, complexed with haptoglobin or can be present in RBC microvesicles (RCMVs). 6 Hemolysis is generally regarded as an undesirable effect and commonly used as a measure of quality. 7 Regulatory agencies license blood storage systems with a requirement that the percent hemolysis not exceed 1% (US Food and Drug Administration) or 0.8% (Council of Europe) with a high degree of statistical assurance at the end of the liquid storage period.
The clinical significance of the presence or extent of hemolysis is unclear. 5, 7, 8 Hemoglobin in solution or in RCMVs could act as a nitric oxide scavenger, causing vasoconstriction in the microcirculation and exacerbating ischemia. [9] [10] [11] Free hemoglobin or released heme could also be used as a source of iron. This is a growth factor for bacteria, 12 or can cause tissue damage resulting in sepsis, 13 or may lead to endothelial cell disruption and vaso-occlusive events. [14] [15] [16] [17] RCMVs express phosphatidylserine and have been shown to facilitate thrombin generation in vitro, 18 or could bind to scavenger receptors in macrophages, 19 possibly inducing cytokine release resulting in fever. There has been considerable interest in the possibility that "older" RBCs may exert deleterious clinical effects based on retrospective observation studies, [20] [21] [22] but such a storage age effect is not seen in all reports. 23 The causative factor(s) for such an effect, if present, is unknown but hemolysis has been suggested as a plausible causative or, at least, a contributory factor. 7 Hemolysis is known to increase with storage duration 5 and is a surrogate marker for the presence and concentration of RCMVs in the supernatant of stored RBCs. 6 Most data on RBC hemolysis have been obtained from experimental in vitro storage conditions, mostly designed to assess hemolysis at the end of liquid storage for licensure or quality assurance purposes. 5, 24 The aim of this study was to assess supernatant hemolysis in a wide range of in-date RBCs, which would be representative of RBC products currently in use in the US. This study examines a difference in hemolysis between different product types and assesses hemolysis in end-of-storage RBC concentrates.
Materials and Methods
This study was approved by the institutional review board of Roger Williams Hospital in Providence, RI. All donations were collected from healthy donors meeting all criteria for allogeneic donations by the Rhode Island Blood Center. RBCs in AS-1 were manufactured from WB and RBC concentrates in AS-3 were manufactured either from WB or by apheresis. Irradiated RBCs were subjected to 2,500 rads using a cesium-137 blood irradiator. All RBC concentrates were prestorage leukoreduced by filtration.
Two populations of RBCs were studied: RBCs on day 42 (day of expiration), which were not subsequently transfused, and RBCs between day 0 and day 42, which were sampled immediately prior to issue for transfusion.
All RBCs were stored in a refrigerator at 1°C to 6°C prior to removal for study. The RBC was weighed and the weight (in grams) was recorded. An empty container was used to tare the container weight and derive the weight of the liquid RBC suspension by subtraction. This weight (in grams) was converted to a volume (in milliliters) using an estimated specific gravity of 1.06. The blood in the container was then gently mixed and inverted. One of the two ports of the container was punctured using an 18 gauge needle attached to a 5-mL syringe and a 2-mL sample removed by slow aspiration. The needle was then removed and two 1-mL aliquots were transferred to EDTA tubes. One aliquot was used for hemoglobin concentration and hematocrit measurement in a Horiba ABX-MICROS 60 (Horiba, Irving, CA). The second aliquot was immediately hard spun using a microprep centrifuge (StatSpin, Norwood, MA) for 5 minutes at 4,160g and the supernatant removed. The hemoglobin concentration in the supernatant was measured using the three wavelength (562 nm, 578 nm, and 598 nm) photometric method. 25 Based on the hematocrit of the RBC, the volume of RBCs was calculated and the volume of the supernatant determined by subtraction of the RBC volume from total product volume. Since all RBCs had a fixed AS volume of 110 mL, the plasma volume was estimated by subtracting 110 mL from the total supernatant volume.
Data were entered into a statistical software application (Epistat, Richardson, TX) and tabulated as descriptive statistics and analyzed either independent t tests, ANOVA, multilinear regression or non-parametric tests, as appropriate. Correlation was Pearson r. Statistical significance was defined as a P < .05. Using a previously observed variance in supernatant hemoglobin in day 42 RBCs, in order to find an arbitrary difference in supernatant hemoglobin of 100 mg/dL between the two populations, a sample size of 93 irradiated and 93 nonirradiated less than day 40 RBCs was estimated.
Results
Day 42 RBCs
Ninety WB-derived RBCs were studied on day 42, of which 77 were group AB, eight group A, and five group O. Twenty-six were AS-1 RBCs and 64 were AS-3 RBCs. The mean hematocrit (±SD), supernatant hemoglobin and residual plasma were 54 ± 4, 75 ± 100 mg/dL and 56 ± 18 mL, respectively. In a univariate analysis, the supernatant hemoglobin showed a relationship to hematocrit (r = 0.4, P < .01), AS (r = −0.3, P < .01) but not residual plasma (r = −0.2, P = .07). On account of this, the RBCs were analyzed separately by AS and shown in ❚Table 1❚. As is evident, there are significant differences between the product types. The AS-3 WB donations are commonly used to manufacture prestorage leukodepleted WB-derived platelet concentrates by in-line filtration, 26 hence are subjected to an initial soft spin resulting in more plasma retained in the RBC concentrate. The AS-1 RBC concentrates are used to manufacture only two components, RBCs in AS and platelet poor plasma. This will explain the higher hematocrits and lower residual plasma in the AS-1 RBC concentrates. Two units of RBCs, both AS-1 with hematocrits of 59 and 62, showed more than 500 mg/dL supernatant hemoglobin. Such concentrations are usually associated with greater than 1% hemolysis, giving a point estimate of 2% (95% CI, 0.3%-7.8%). A multilinear regression analysis with supernatant hemoglobin as output variable and hematocrit, AS and residual plasma as input variables showed an effect of hematocrit (P < .01) but not AS (P = .1) nor residual plasma (P = .8).
The 90 products were then separated by hematocrit (arbitrarily ≤55% or >55%), regardless of AS, and are illustrated in the dot plots in ❚Figure 1❚. The affect of higher product hematocrit on the supernatant hemoglobin on day 42 is evident.
RBCs <40 Days
218 RBCs were studied immediately prior to dispensing. 142 were Group O, 53 were Group A, 20 were Group B, and 3 were Group AB. These RBCs were either WBderived in AS-1, (n = 65), WB-derived in AS-3 (n = 115), or apheresis-derived (APD) RBCs in AS-3 (n = 38). All were between 7 and 39 days of liquid storage at the time of sampling with a median of 22 days. Eighty-six were irradiated prior to dispensing and 132 were not.
In a univariate analysis, supernatant hemoglobin showed a relationship to hematocrit (r = 0.4, P < .01), storage age (r = 0.2, P < .01), residual plasma (r = -0.4, P < .01), and AS (r = 0.3, P = .01). However, a multilinear regression analysis showed only an effect of hematocrit (P < .01) and storage age (P < .01) and not residual plasma (P = .1) or AS (P = .2). The statistically significant but weak storage age relationship to supernatant hemoglobin is illustrated in the scattergram and regression line in ❚Figure 2❚. These in-date products were then stratified by arbitrary storage age categories relevant to recent storage age studies and illustrated in dot plots in ❚Figure 3❚. Although a statistically significant difference is present between categories (H = 21.3, P < .05) median supernatant hemoglobin increased only slightly with storage age, and there is considerable overlap even between RBCs less than 10 days and those greater than 21 days ( Figure  3) . No difference was seen in supernatant hemoglobin between the irradiated and the nonirradiated RBCs, (26.2 ± 20 mg/dL vs 24.8 ± 12.8 mg/dL, respectively; P = .6), although the irradiated RBCs had been stored for only a median of 8 days postirradiation (range, 0-24 days) and prior to sampling and issue.
The 218 RCCs were separated into the six different product types and are shown in ❚Table 2❚. The mean storage age of these six product types did differ statistically (P = .038) but the extent of the difference in storage age would be unlikely to materially affect the supernatant hemoglobin ( Figure 2 ). No differences were observed between the irradiated and non-irradiated products within each product type. Comparing WB-derived products, the AS-1 RBCs showed higher supernatant hemoglobin than the AS-3 (P = .02), consistent with the day 42 RBCs data, but such a difference is not present between the WB AS-1 RBCs and the APD AS-3 RBCs (P = .3). As is evident, the hematocrit in the APD AS-3 RBCs is higher than the hematocrit in the WB-derived AS-3 RBCs (Table 2) . Using multilinear regression analysis within these six subpopulations, supernatant hemoglobin was independently associated with both storage age and hematocrit for most categories (data not shown). These 218 RBCs showed a difference in supernatant hemoglobin to the 90 day 42 RBCs (25.5 ± 16 vs 75 ± 100 mg/dL; P < .01) ❚Figure 1❚ Supernatant hemoglobin (Hb) in the ninety day 42 RBCs separated into two arbitrary groups by hematocrit. Horizontal bars are the medians.
Discussion
There is considerable interest in the potential significance of free hemoglobin, heme, or RCMV's in the pathophysiology of disease, focusing on a predisposition to either thrombosis [14] [15] [16] [17] 27 or bacterial infection. 13 Both hereditary hemolytic disorders [28] [29] [30] (sickle cell disorders, thalassemias) and acquired hemolytic disorders [31] [32] [33] (paroxysmal nocturnal hemoglobinuria and autoimmune hemolysis) have been shown to be associated with thrombosis. In vitro hemolysis of stored allogeneic cells has a different basis and is likely a consequence of the metabolic failure of the stored RBCs. 1 Some studies have reported a clinical prothrombotic effect of RBC transfusion. 34, 35 However, a recent meta-analysis of randomized controlled trials (RCTs) of restrictive vs liberal RBC transfusion failed to show any such thrombotic effect 36 and, therefore, the issue is unsettled at this time. Bacterial infection may be exacerbated by the availability of iron as a growth factor 12 and there are several recent reports of an association of RBC transfusion with an increased incidence of infectious complications, [36] [37] [38] [39] [40] [41] but the causal association with either free heme or RCMV's is not established at this time.
The relationship of hemolysis to storage age and the relationship of the latter to clinical complications of transfusion continues to remain controversial with some reports suggesting a storage age effect [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and others, no such effect. [56] [57] [58] [59] [60] [61] [62] Four RCTs of fresh vs either older RBCs or standard of care RBCs have shown no differences in clinical outcome and are discordant with observational studies. 66 A metanalysis of trials failed to show a deleterious effect of storage age. 67, 68 Possible explanations are confounding by different RBC product types (AS) or that a clinically material storage effect, if present, may only be present in a subpopulation of older RBCs at the extreme of the storage period. [69] [70] [71] [72] Our data show that there are differences between product types, which is a potential confounder not considered in the design of these RCTs. [63] [64] [65] [66] Furthermore, our data suggest that the extremes of hemolysis only occur at the end of the liquid storage period consistent with other data. 70 Furthermore, there is a recent report showing increased morbidity associated with the transfusion of RBCs greater than 35 days. 72 Hence, patients randomized to RBCs with less than 10 days of storage as "fresh" RBCs would be transfused with RBC products that are not materially different from standard of care or many greater than 21 day RBC products, based on hemolysis. Even if some products were greater than 35 days, the supernatant changes might not be significantly different (Figure 3) , depending on the product transfused. But if some patients were to receive older products (>35 days) with a higher degree of hemolysis (Figure 1 ), this could potentially predispose to an untoward effect such as bacterial infection or a thrombotic event. This might help explain the discordancy in retrospective observational studies which have been interpreted as showing a storage age effect [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] when the RCTs do not. [63] [64] [65] [66] There are limitations to our study. First, it is unclear whether supernatant hemoglobin concentration is related directly or could be a surrogate as to the cause of any adverse events in recipients. Second, no defined threshold of supernatant hemoglobin is recognized as deleterious, although high levels of supernatant hemoglobin (>500 mg/ dL) are associated with unacceptable regulatory thresholds of percent hemolysis. Third, we did not conduct any active surveillance for transfusion reactions, but it is unlikely with this sample size that we would be able to show a relation between supernatant hemoglobin and any observed reaction. Lastly, we have used supernantant hemoglobin rather than percent hemolyis to characterize the supernatants, since this is measured directly while the calculation for percent hemolysis requires an accurate measurement of the RBC suspension volume. The accuracy of the volume of the RBC suspension depends on the appropriateness of the tare weight and the specific gravity of 1.06, which could introduce error in the estimation. The strength is that this is the first study measuring supernatant hemoglobin in a wide storage age range of in-date RBC concentrates.
Our data shows that both hematocrit and storage age influence hemolysis. For WB donations, the product hematocrit will largely be determined by the donor hematocrit and primary centrifugational conditions for any fixed volume of collection, since the supernatant is mostly AS with a fixed volume. This will be higher in male than female donors. Thus male donors may result in higher hematocrit products and greater hemolysis, especially at the end of liquid storage. An important hereditary predisposition to in vitro hemolysis has recently been shown, so that intersubject genetic variability is now recognized as an important determinant of hemolysis. 73 This introduces greater heterogeneity and using storage age in a univariate analysis provides an incomplete picture of the storage lesion effect in any one RBC. Our data show differences in supernatant hemoglobin between RBC concentrates less than 40 days and those greater than 40 days and suggest that sampling and characterization of the RBC suspension immediately prior to issue would seem justified, if future studies seek to examine for a deleterious effect of RBC transfusion in transfusion recipients. The storage age for the irradiated RBCs is the duration of liquid storage prior to irradiation plus the duration of storage postirradiation.
